Janssen Pharmaceutica Nv

Ortho-mcneil Pharmaceutical Corp.

Kelly J McClure

Michael D Hack

Alec D Lebsack

Natalie Anne Hawryluk

Wendy Eccles

Steven P Meduna

John M Keith

Jing Liu

Mark D Rosen

Paul J Krawczuk

William Moore Jones

Anne E Fitzgerald

Hariharan Venkatesan

J Guy Breitenbucher

David A Kummer

Kevin Douglas Kreutter

Rachel T Nishimura

Genesis M Bacani

Alice Lee-Dutra

James Patrick Edwards

Neelakandha S Mani

Liming Huang

Steven D Goldberg

Laurent Gomez

Jennifer Diane Venable

Jianmei Wei

Daniel J Pippel

Gavin C Hirst

Wenying Chai

Xiaohua Xue

Craig R Woods

Virginia M Tanis

Zachary S Sales

J Kent Barbay

Amy Y Shih

Cheryl A Grice

Ronald L Wolin

Aihua Wang

Kristi A Leonard

Maxwell David Cummings

Maud J Urbanski

Brett D Allison

Bryan James Branstetter

Umar Maharoof

Kent Barbay

Jeffrey E Merit

Scott D Bembenek

Frank Urban Axe

Aaron M Kearney

Adrienne M Landry-Bayle

Kristen L Arienti

Nigel P Shankley

Alice Lee

Clark A Sehon

Taraneh Mirzadegan

Terrance D Barrett

Magda F Morton

Anne Fourie

Alejandro Santillán, Jr

Connor L Martin

Elizabeth G Fennema

Matthew T Epperson

Alexandro Santillán, Jr

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Inhibitors of KEAP1-Nrf2 protein-protein interaction

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein the syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula I.

6-aminopyridin-3-yl thiazoles as modulators of ROR&#x3b3;T

The present invention comprises compounds of Formula I. wherein: The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR&#x3b3;t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim

Quinolinyl modulators of ROR&#x3b3;t

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

Flap modulators

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, L and Rare as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.

FLAP modulators

The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R, R, R, R', L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention. 

Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.

Tetrahydro-pyrimidoazepines as modulators of TRPV1

Growing community of inventors

San Diego, CA, United States of America

Kelly J McClure